Lakewood-Amedex Biotherapeutics announced its direct listing on the Nasdaq Capital Market, with its common stock beginning trading on April 23, 2026 under the ticker “LABT.” The Sarasota, Florida-based clinical-stage biotechnology company is developing its proprietary Bisphosphocin® class of fast-acting, broad-spectrum antimicrobials, with lead product candidate Nu-3 being advanced as a potential treatment for infected diabetic foot ulcers.
The company expects the listing to support the accelerated development of its pipeline and plans to initiate a Phase 2a clinical trial for Nu-3 in the near term.
Lucosky Brookman LLP acted as counsel to Lakewood-Amedex Biotherapeutics in connection with the direct listing.
